Onconetix, Inc. (ONCO)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.56
- As of
Kresmion compiles this page from ONCO's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Onconetix, Inc. (ONCO): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
See the full ONCO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ONCO on one page. Preview it with sample data, then open it live with a free account.
Preview the ONCO dossierActive signals for ONCO
- mediumEARNINGS_BEAT
Q1-2023: Beat consensus by 16.0% - EPS $-30600 vs $-36414 estimate
- mediumEARNINGS_MISS
Q2-2023: Missed consensus by 37.3% - EPS $-35700 vs $-26010 estimate
- mediumEARNINGS_MISS
Q3-2023: Missed consensus by 39.3% - EPS $-45900 vs $-32946 estimate
- mediumEARNINGS_BEAT
Beat consensus by 16.0% - EPS $-30600 vs $-36414 estimate
- mediumEARNINGS_MISS
Missed consensus by 37.3% - EPS $-35700 vs $-26010 estimate
FREE, NO ACCOUNT
Every signal on ONCO, as it fires
You are seeing 5 of 9 signals recorded on ONCO since 2026-05-26.
The five above landed across 2 days. The other 4 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, ONCO
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ONCO against its peers
ONCO's operating margin of -2190.0% ranks in the 59th percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | ONCO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 815371 USD | 131000 USD | 71 | 11 |
| Gross margin | 77.6% | 59.6% | 50 | 8 |
| Operating margin | -2190.0% | -5143.5% | 59 | 10 |
| Net margin | -1721.0% | -4911.4% | 68 | 10 |
| Return on equity | -89.0% | -214.2% | 81 | 17 |
| 1 year | -99.7% | -92.9% | 4 | 13 |
Peers (20): CVKD, MBIO, HCWB, SXTP, APVO, REVB, JUNS, BRTX, CLDI, PPCB, ADTX, MTNB, VIVS, SILO, GOVX, ERNA, GRI, PMCB, PCSA, EMMA. Left out: MLEC (period gap), XRTX (no annual filing), NYMXF (period gap), VCNX (period gap), LSBCF (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (ONCO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow ONCO on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to ONCO for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.